1228594-41-9 Usage
Derivative of biphenyl
Aromatic hydrocarbon The compound is derived from biphenyl, which is an aromatic hydrocarbon consisting of two connected benzene rings.
Hydroxymethyl group
Attached to the biphenyl ring A hydroxymethyl group (-CH2OH) is attached to one of the benzene rings in the biphenyl structure.
Carbaldehyde functional group
Attached to the biphenyl ring A carbaldehyde functional group (-CHO) is attached to the other benzene ring in the biphenyl structure.
Use in organic synthesis
Reagent and building block This compound is commonly used as a reagent and building block in the preparation of various pharmaceuticals and agrochemicals.
Unique structure and reactivity
The specific arrangement of the hydroxymethyl and carbaldehyde groups on the biphenyl ring gives this compound its unique structure and reactivity, making it useful in the development of new drugs and materials.
Potential applications
Organic electronics and chiral ligand synthesis 2'-(HYDROXYMETHYL)-[1,1'-BIPHENYL]-4-CARBALDEHYDE has potential applications in the field of organic electronics and as a starting material for the synthesis of chiral ligands.
Check Digit Verification of cas no
The CAS Registry Mumber 1228594-41-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,5,9 and 4 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1228594-41:
(9*1)+(8*2)+(7*2)+(6*8)+(5*5)+(4*9)+(3*4)+(2*4)+(1*1)=169
169 % 10 = 9
So 1228594-41-9 is a valid CAS Registry Number.
1228594-41-9Relevant articles and documents
VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection
Da Costa, Laurène,Roche, Manon,Scheers, Els,Coluccia, Antonio,Neyts, Johan,Terme, Thierry,Leyssen, Pieter,Silvestri, Romano,Vanelle, Patrice
, p. 453 - 462 (2016/04/19)
Human rhinoviruses (HRV) are the predominant cause of common colds and flu-like illnesses, but are also responsible for virus-induced exacerbations of asthma and chronic obstructive pulmonary disease. However, to date, no drug has been approved yet for clinical use. In this study, we present the results of the structure-based lead optimization of a class of new small-molecule inhibitors that we previously reported to bind into the pocket beneath the canyon of the VP1 protein. A small series of analogues that we designed based on the available structure and interaction data were synthesized and evaluated for their potency to inhibit the replication of HRV serotype 14. 2-(4,5-Dimethoxy-2-nitrophenyl)-1-(4-(pyridin-4-yl)phenyl)ethanol (3v) was found to be a potent inhibitor exhibiting micromolar activity (EC50 Combining double low line 3.4 ± 1.0 μM) with a toxicity for HeLa cells that was significantly lower than that of our previous hit (LPCRW-0005, CC50 Combining double low line 104.0 ± 22.2 μM; 3v, CC50 > 263 μM).
